NCT07807163
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07807163
Title A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC (FORTIFI-FLEX)
Acronym FORTIFI-FLEX
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bicara Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.